| scholarly article | Q13442814 |
| P2093 | author name string | Jian Huang | |
| Ke Zhang | |||
| Lixia Chen | |||
| Jinhui Wang | |||
| Guihua Wang | |||
| Suyu Gao | |||
| Yingnan Jiang | |||
| P2860 | cites work | Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2. | Q54333619 |
| The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases. | Q54540532 | ||
| Design, synthesis and evaluation of highly selective pyridone-based class II MET inhibitors. | Q55073600 | ||
| Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor | Q24294589 | ||
| Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product | Q24310794 | ||
| Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor | Q24564783 | ||
| Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations | Q27660113 | ||
| Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors | Q27687506 | ||
| Development and testing of a general amber force field | Q29547642 | ||
| GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit | Q29615867 | ||
| The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma | Q30494514 | ||
| BAY 43-9006: preclinical data | Q30736965 | ||
| Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities | Q33636098 | ||
| Development of c-MET pathway inhibitors | Q34198905 | ||
| Scatter-factor and semaphorin receptors: cell signalling for invasive growth | Q34632043 | ||
| Drug development of MET inhibitors: targeting oncogene addiction and expedience | Q34782774 | ||
| From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer | Q34939284 | ||
| Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity | Q34959266 | ||
| Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling | Q36020888 | ||
| Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells | Q36236279 | ||
| Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors | Q36723753 | ||
| Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair | Q37357884 | ||
| Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). | Q37965292 | ||
| Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors | Q39028418 | ||
| Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents | Q39196016 | ||
| Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series. | Q39399221 | ||
| Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency. | Q39641906 | ||
| BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring | Q39741030 | ||
| N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases | Q39777862 | ||
| Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer | Q39911616 | ||
| The effect of platelet-rich plasma on the regenerative therapy of muscle derived stem cells for articular cartilage repair. | Q44812445 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2016-05-11 | |
| P1433 | published in | Molecules | Q151332 |
| P1476 | title | Discovery of Potent c-MET Inhibitors with New Scaffold Having Different Quinazoline, Pyridine and Tetrahydro-Pyridothienopyrimidine Headgroups | |
| P478 | volume | 21 |
Search more.